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GH, IGF-1, and insulin are emerging as important and independent mediators of tumor development and
aging. Two recent studies report that humans with GH-receptor deficiency are protected from developing
cancer through alterations in GH, IGF-1, and insulin signaling, decreasing the susceptibility of cells to DNA
damage and abnormal proliferation.The growth hormone (GH) and insulin-like
growth factor-1 (IGF-1) systems are crit-
ical for normal growth and development,
particularly during puberty, when GH
stimulates a surge in IGF-1 levels, leading
to the normal pubertal growth spurt. While
many of the functions of GH are mediated
by IGF-1, both hormones may also act
independently in various tissues. The
metabolic effects of GH generally oppose
those of insulin, whereas those of IGF-1
may support the role of insulin in metabo-
lism. As one ages, there is a gradual but
continuous reduction in circulating GH
and IGF-1 levels beginning in the third or
fourth decade of life (Parekh et al.,
2010). These reduced levels may be
partially responsible for the visceral
adiposity, sarcopenia, osteoporosis, and
other untoward changes associated with
advancing age; however, these reduc-
tions may protect against cancer devel-
opment (Parekh et al., 2010; Perrini
et al., 2010;Major et al., 2010). Two recent
studies that have attracted much atten-tion within and outside the scientific
community show that individuals with
Laron syndrome (GH receptor [GHR] defi-
ciency) have a greatly reduced, almost
absent, risk of cancer compared with indi-
viduals from the same family without the
receptor deficiency (Steuerman et al.,
2011; Guevara-Aguirre et al., 2011).
Laron syndrome is due to a mutation in
the GHR that leads to reductions in circu-
lating IGF-1 and consequent short
stature. These patients are resistant to
endogenous GH, as well as GH therapy,
due to the receptor abnormality, but clini-
cally respond quite well to rhIGF-1 injec-
tions. In the first study, Steuerman et al.
examined 230 individuals with this
disorder and found no cases of cancer,
while 8.3% of their first-degree relatives
and 22.1% of further family members
without the disorder developed various
forms of cancer (Steuerman et al., 2011).
In the second study, an Ecuadorian
cohort of individuals with the same
syndrome showed a similar result, withno cancer deaths among a population of
99 individuals and only one case of
ovarian carcinoma. In their relatives,
cancer accounted for 20% of all deaths
(Guevara-Aguirre et al., 2011). This led
both groups to postulate that the reduc-
tion in circulating levels of IGF-1 pro-
tected against cancer development.
Indeed, human mammary epithelial cells
cultured in the serumof theGHR-deficient
(GHRD) Ecuadorian cohort of patients,
were protected from oxidative DNA
damage, compared with cells cultured in
the serum of their relatives. In the setting
of oxidative stress, increased cytotoxicity
was also seen in the cells cultured in the
serum from the GHRD patients, while the
addition of IGF-1 to this serum or culturing
cells in the serum from controls reduced
the rate of cell death. In association with
these findings, the investigators reported
upregulation of proapoptotic genes, as
well as the mitochondrial superoxide dis-
mutase SOD2, and downregulation of
genes involved in cell-cycle progression,13, April 6, 2011 ª2011 Elsevier Inc. 355
Figure 1. Potential Mechanisms Leading to the Decreased Rates of Cancer and Diabetes
Seen in Individuals with Laron Syndrome
Growth hormone receptor deficiency (GHRD) leads to GH resistance with resultant decreased hepatic
IGF-1 production and consequently increased circulating GH levels due to increased pituitary GH secre-
tion. GH resistance also causes increased insulin sensitivity and decreased insulin levels. The combination
of GH resistance, reduced insulin, and IGF-1 may contribute to decreased cancer development. Dimin-
ishedGH signaling leads to increased abdominal obesity, which usually is associated with increased rates
of type 2 diabetes mellitus (T2DM); however, in patients with Laron syndrome, there is a lower rate of
T2DM, despite increased abdominal adiposity, probably due to lower insulin resistance.
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Previewsmotility, and gene expression (Guevara-
Aguirre et al., 2011). GHRD therefore
appears to protect cells from oxidative
damage and to increase apoptotic path-
ways. In the presence of IGF-1, cells
may accumulate more DNA damage and
are protected from apoptosis, therefore
increasing the likelihood of cancer cells
proliferating. These studies thus support
the concept that reductions in GH and
IGF-1 seen with aging may be important
in protecting against the development of
cancer, by altering cellular susceptibility
to DNA damage and apoptosis.
A second interesting phenomenon
described by Guevara-Aguirre et al. was
the lack of diabetes in the Ecuadorian
cohort, despite the commonly described
visceral adiposity seen in Laron syndrome
patients (Guevara-Aguirre et al., 2011).
GH normally increases adipocyte lipolysis
and reduces adiposity, so their resistance
to GH could explain their visceral
adiposity. Given that visceral adiposity is
thought to play a major role in the devel-356 Cell Metabolism 13, April 6, 2011 ª2011opment of the metabolic syndrome and
lead to type 2 diabetes in genetically pre-
disposed individuals, it was surprising to
find virtually no diabetes in this cohort.
One possible explanation for this unex-
pected finding is the GH resistance, as
GH normally antagonizes insulin action,
causing increased insulin resistance.
Thus, a lack of GH signaling would
decrease insulin resistance. Indeed, these
individuals have lower levels of insulin
and greater insulin sensitivity than their
relatives.
GH, IGF-1, and insulin may be indepen-
dently involved in cancer development
and progression (Figure 1) (Gallagher
and LeRoith, 2010). Therefore, many un-
answered questions remain. Is it the lack
of GH signaling, IGF-1, IGF-2, or hyperin-
sulinemia that explains the absence of
cancer in Laron syndrome patients?
Answering this question may help in the
further development of tools to inhibit
cancer in the older ‘‘normal’’ population.
Also, how do these factors affect aging?Elsevier Inc.Interestingly, neither study showed an
increase in longevity, even though studies
in C. elegans, Drosophila, and mice show
that life span is significantly extended by
inhibiting the insulin/IGF-1 signaling path-
ways (Kenyon, 2001; Coschigano et al.,
2003; Wu et al., 2003; Weindruch et al.,
1986). In mice, reduced rates of cancer
were also observed (Coschigano et al.,
2003; Wu et al., 2003; Weindruch et al.,
1986). In humans, epidemiological
studies have demonstrated that relative
increases in IGF-1 and insulin levels may
be associated with an increased risk of
cancer development. Additional studies
of individuals with increased GH and
IGF-1 due to acromegaly suggest that
increased GH may also add to the risk of
tumor growth in certain tissues. Also,
what is the explanation for the lack of dia-
betes? Is it only the lack of GH antago-
nism of insulin or is there an additional
genetic explanation? These answers will
come from further studies in this and other
populations, as well as from the rest of the
animal kingdom.Meanwhile, these results
of GH resistance reinforce the need for
caution in using rhGH therapies to avoid
the aging process.
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